NASDAQ:GANX Gain Therapeutics Q3 2026 Earnings Date & Estimates $1.14 -0.01 (-0.43%) As of 11:42 AM Eastern This is a fair market value price provided by Massive. Learn more. Gain Therapeutics is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. The conference call is scheduled for November 13, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 11, 2026TimeBefore Market OpensConference Call DateNovember 13, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Gain Therapeutics in Q3 2026Gain Therapeutics is expected to post earnings of -$0.13 per share on revenue of $33 thousand. In the same quarter a year earlier Gain Therapeutics reported -$0.15 per share. Gain Therapeutics last reported on August 11, 2026, posting -$0.11 per share and beating the -$0.1380 consensus estimate. Gain Therapeutics has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.13Expected Revenue$33 thousandPrior-Year EPS-$0.15Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.11 (Beat by +$0.0280)EPS Beat Rate3 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Gain Therapeutics Q3 2026 Earnings FAQ When does Gain Therapeutics report Q3 2026 earnings? Gain Therapeutics (NASDAQ:GANX) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Gain Therapeutics' Q3 2026 earnings call? Gain Therapeutics' Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Gain Therapeutics? Analysts expect Gain Therapeutics to post earnings of -$0.13 per share for Q3 2026. How much revenue is Gain Therapeutics expected to report? The consensus revenue estimate for Gain Therapeutics is $33 thousand for Q3 2026. Gain Therapeutics Earnings HeadlinesGain Therapeutics, Inc. (NASDAQ:GANX) Stock Has Consensus Price Target of $7.67October 29, 2026 | americanbankingnews.comSibylla Biotech Appoints Usman Azam CEO, Gianluca Fuggetta CFO, and Expands Executive Team to Drive Transition to ClinicOctober 13, 2026 | globenewswire.comDr. Ron Paul: “It’s time to prepare”The Pentagon has plans for military bases to survive a 90-day disaster. A former Defense Intelligence Agency staffer warns that the window to prepare, even with the basics, is closing. Dr. Ron Paul, 12-term former Congressman, says tech stocks are already in bear market territory while AI-driven cyberattacks grow by the day. He's teamed up with a leading financial expert to explain how he's preparing.November 4 at 1:00 AM | Stansberry Research (Ad)Gain Therapeutics to Attend the 2026 Maxim Growth SummitOctober 8, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Nexalin Technology, Inc. (NXL) and Gain Therapeutics (GANX)October 4, 2026 | theglobeandmail.comGain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months AdministrationOctober 1, 2026 | globenewswire.comSee More Gain Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Gain Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gain Therapeutics and other key companies, straight to your email. Email Address About Gain TherapeuticsGain Therapeutics (NASDAQ:GANX) is a biotechnology company focused on developing small-molecule therapies for diseases associated with lysosomal dysfunction, including neurodegenerative and rare disorders. The company’s approach is designed to identify compounds that bind to and modulate disease-related proteins, with the goal of restoring their function and addressing underlying disease mechanisms. Gain Therapeutics’ lead investigational program, GT-02287, is an orally administered, brain-penetrant small molecule being developed for GBA1-associated Parkinson’s disease. The program is intended to activate or stabilize glucocerebrosidase, an enzyme whose impaired function is linked to a genetic subset of Parkinson’s disease and other lysosomal disorders. GT-02287 remains an investigational product and has not been approved for commercial use. The company uses its proprietary allosteric small-molecule discovery platform to pursue additional treatments for central nervous system and lysosomal diseases. Gain Therapeutics is headquartered in Bethesda, Maryland, and its programs are being advanced through clinical and preclinical development for potential use in patients in international markets.View Gain Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Advanced Micro Devices' Q3 Results Answer a Big Question, But Another Remains3 Dividend Increases Above 10%, But Which Offers the Most Income?High Voltage Returns: Talen Energy Powers the Data Center RushMarriott's Earnings Beat Shows Why It's More Than a Bet on Travel DemandPalantir's $2.3 Billion Quarter Puts Its Premium Valuation to the TestTower Semiconductor's Earnings Are Soaring—So Why Is Its Stock Down More Than 50%?Apple's Earnings Beat Comes With a Catch for Investors Heading Into the Holidays Upcoming Earnings Airbnb (11/5/2026)Sony (11/5/2026)Toyota Motor (11/5/2026)Monster Beverage (11/5/2026)Canadian Natural Resources (11/5/2026)ConocoPhillips (11/5/2026)EOG Resources (11/5/2026)Targa Resources (11/5/2026)TC Energy (11/5/2026)Becton, Dickinson and Company (11/5/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
